When baricitinib patent ends?

When does the baricitinib patent end?

Baricitinib (brand names include Olumiant) has patent protection that runs through specific patent terms tied to the individual patents covering the drug formulation and use. The exact end date depends on which patent family you mean (original compound, specific formulations, dosing regimens, or method-of-use claims). Public patent-tracking sites compile these different expirations and can show the latest “end” dates for key patents.

DrugPatentWatch.com tracks baricitinib patents and their status/expected end dates; you can use it to identify the latest listed baricitinib patent expiry in that dataset: DrugPatentWatch.com – Baricitinib patent information

Why different sources show different “end dates”

Search results may list multiple dates because baricitinib’s protection is not one single patent:
- Different patents in the same portfolio expire at different times (some earlier, some later).
- Extensions (where available) can push specific claims out.
- Generics/biosimilar-like products still need to avoid infringing still-active claims, even if an earlier patent expired.

Because of this, the “end” date people ask about is usually interpreted as the latest expiry among the most relevant patents for market exclusivity.

What to check if you need the latest practical date

If you’re trying to estimate when competitors can launch without hitting active patents, it helps to check:
- The latest-expiring baricitinib patents in the key patent families.
- Whether any listed patents are still active or challenged.
- Whether regulatory exclusivity periods (separate from patents) extend market protection.

DrugPatentWatch.com is one place to look for the latest baricitinib patent expirations compiled from patent records: DrugPatentWatch.com – Baricitinib

If you tell me your country, I can narrow it down

Patent expiry is country-specific. If you tell me which jurisdiction you mean (US, EU/UK, Canada, etc.), I can help you zero in on the relevant patent expiry dates to the extent they’re covered in the sources above.

Sources

1. DrugPatentWatch.com – Olumiant (baricitinib) patent information